About this trial
With the younger patients diagnosed with asymptomatic leiomyoma, delay in the reproductive age of women, the advancement of medical technology, and the rapid development of treatment methods, there are many choices between gynecologists, gynecologists and patients because of experience and knowledge. It is not easy to make the most favorable choice for patients. This study is mainly led by a committee composed of designers, doctors, nurses and patients, and based on clinical guidelines and evidence-based medicine. Co-operating with patients with asymptomatic small leiomyoma, we want to find the influencing factors of clinical decision-making, and to establish a patient decision aid tool. We use prospective trial to verify that the use of this tool can improve patients' decision-making efficacy and further improve patient-reported outcomes.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Diagnosis of leiomyoma: patients with leiomyoma diagnosed by imaging examinations (ultrasound and MRI) have no clinical symptoms;
Female with age in 18-55 years old;
The maximum diameter of a single leiomyoma is less than 5m, and the number does not exceed 10 by MRI;
No contraindications for sedation and analgesia;
Disqualifiers
History of myomectomy, including transabdominal, laparoscopic, hysteroscopy, etc.;
History of connective tissue diseases or radiotherapy, especially abdominal radiotherapy;
With pregnancy, acute inflammation of the reproductive tract, or other gynecological benign and malignant diseases such as endometriosis and ovarian tumors;
The maximum diameter of leiomyoma is greater than or equal to 5cm;
Trial population
18-55 years old woman diagnosed with uterine fibroids and without clinical symptoms
Trial design
Case-control
Prospective
Treatments tested in this trial
Patients Decision Aids
Other interventionPatient Decision Aids (PDAs) are an important way to facilitate making decision by patients, helping patients make specific and prudent choices by providing information about treatment options and corresponding outcomes, including benefits and risks, related to their health status. The purpose of PDAs is to encourage patients to participate in decision-making. It makes it easier for patients and doctors to discuss treatment options. It effectively promotes communication between patients and doctors. It can help patients combine their own needs and professional advice to make better, more individualized diagnosis and treatment options.
Treatment groups
Trial outcomes
Primary outcomes
Patient satisfaction after using PDAs
The patients in PDAs will undertake the treatment by PDAs. And we will collect the satisfaction after 12 months.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.